WPD Pharmaceuticals Inc. (C:WBIO)
Business Focus: Bio Therapeutic Drugs
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| Company Contact | |
| Address: | Suite 1080, 789 West Pender Street VANCOUVER BC V6C 1H2 |
| Tel: | N/A |
| Website: | https://www.wpdpharmaceuticals.com |
| IR: | See website |
| Key People | ||
| Mariusz Olejniczak Chief Executive Officer | Michael Malana Chief Financial Officer | Liam Lake Corcoran Canadian Vice President of Legal, Corporate Secretary, Director |
| Business Overview |
| WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in clinical development stage and three in pre-clinical development. It operates its business primarily through WPD Poland, a subsidiary of and the operating branch of the Company. Its portfolio includes WPD101, Berubicin, and WPD103. WPD101 is a family of biopharmaceuticals in preclinical stages of development for targeted treatment of brain tumors with a global license. Berubicin is an anthracycline proven to cross the blood-brain barrier and able to reach brain tumors. |
| Financial Overview |
| For the nine months ended 30 September 2021, WPD Pharmaceuticals Inc revenues was not reported. Net loss decreased 46% to C$3.1M. Lower net loss reflects Share-based payments decrease of 96% to C$138K (expense), Other income increase from C$795K to C$1.7M (income), Marketing and advertising decrease of 81% to C$70K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -C$0.05 to -C$0.03. |
| Reporting Currency: | Canadian Dollars |
| Enterprise value: | $3.81M as of Sep 30, 2021 |
| Annual revenue (TTM): | $0.00M as of Sep 30, 2021 |
| EBITDA (TTM): | -$6.13M as of Sep 30, 2021 |
| Net annual income (TTM): | -$4.86M as of Sep 30, 2021 |
| Free cash flow (TTM): | -$1.37M as of Sep 30, 2021 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 113,438,244 as of Sep 30, 2021 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2023 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.